A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : ERG / Evidence Review Group

[Related PubMed/MEDLINE]
Total Number of Papers: 144
[Display Entries]
100 entries :
     (Publication year, Descending)
100 entries :
     (Publication year, Ascending)
>> all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   ERG  (>> Co-occurring Abbreviation)
Long Form:   Evidence Review Group
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2019 Ceritinib for Untreated Anaplastic Lymphoma Kinase-Positive Advanced Non-Small-Cell Lung Cancer: An Evidence Review Group Evaluation of a NICE Single Technology Appraisal. ALK, CHE, CS, CT, MAIC, NICE, NSCLC, PAS, PFS, RCT, STA
2019 Eribulin for Treating Locally Advanced or Metastatic Breast Cancer After One Chemotherapy Regimen: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. AC, ICER, NICE, OS, PFS, QALY, STA
2019 How Do Pharmaceutical Companies Model Survival of Cancer Patients? A Review of NICE Single Technology Appraisals in 2017. NICE, TSD
2019 Ibrutinib for Treating Relapsed or Refractory Mantle Cell Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. CrI, HR, ICER, MCL, NHS, NICE, NMA, PAS, PFS, QALY, R-chemo, R/R
2019 Ibrutinib for Treating Waldenstrom's Macroglobulinaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. CDF, ICER, NHS, NICE, PAS, PFS, PSS, QALY, R/R, STA, WM
2019 Nivolumab for Treating Metastatic or Unresectable Urothelial Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. NICE, STA, STC
2019 Pembrolizumab for Previously Treated Advanced or Metastatic Urothelial Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. CPS, ITT, MSD, NICE, OS, PD-L1, PFS
2019 Pembrolizumab for Treating Relapsed or Refractory Classical Hodgkin Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. NICE, RRcHL, SOC, STA
2019 The Clinical and Cost Effectiveness of Inotuzumab Ozogamicin for the Treatment of Adult Relapsed or Refractory B-Cell Acute Lymphoblastic Leukaemia: An Evidence Review Group Evaluation of a NICE Single Technology Appraisal. HSCT, ICER, NICE, QALYs, SOC
10  2018 Arsenic Trioxide for Treating Acute Promyelocytic Leukaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. AC, AIDA, APL, ATO, ATRA, CS, ICER, KSR, NICE, QALYs, RCTs
11  2018 Autologous Chondrocyte Implantation with Chondrosphere for Treating Articular Cartilage Defects in the Knee: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. ACI, MACI, MF, NICE, NMA, RCT, STA
12  2018 Baricitinib for Previously Treated Moderate or Severe Rheumatoid Arthritis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. BARI, CS, CTZ, DMARDs, ICER, MTX, NHS, NMAs, PSA, QALY, RA, RTX, TNFi-IR
13  2018 Dinutuximab Beta for Treating Neuroblastoma: An Evidence Review Group and Decision Support Unit Perspective of a NICE Single Technology Appraisal. BMJ-TAG, DSU, ICER, IL, MAIC, NICE, PAS, QALY, RCT, STA
14  2018 Etelcalcetide for Treating Secondary Hyperparathyroidism: An Evidence Review Group Evaluation of a NICE Single Technology Appraisal. CKD, ICER, NICE, PAS, PBVD, PTH, QALY, RCTs, SHPT, SHTAC, STA
15  2018 Mepolizumab for Treating Severe Eosinophilic Asthma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. AC, CI, ICER, ITT, MENSA, mOCS, NICE, PAS, QALY, RR, ScHARR-TAG, SOC, STA
16  2018 Obinutuzumab in Combination with Chemotherapy for the First-Line Treatment of Patients with Advanced Follicular Lymphoma : An Evidence Review Group Evaluation of the NICE Single Technology Appraisal. FL, FLIPI, ICER, KSR, NICE, QALY, STA
17  2018 Obinutuzumab with Bendamustine for Treating Follicular Lymphoma Refractory to Rituximab: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. FL, NICE, OS, PFS
18  2018 Olaratumab in Combination with Doxorubicin for the Treatment of Advanced Soft Tissue Sarcoma: An Evidence Review Group Perspective of a National Institute for Health and Care Excellence Single Technology Appraisal. CAA, ICERs, NHS, NICE, QALY, STS
19  2018 Paclitaxel as Albumin-Bound Nanoparticles with Gemcitabine for Untreated Metastatic Pancreatic Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. AC, GEM, ICERs, NICE, NMA, OS, PAS, PFS, PH, QALY, STA
20  2018 Pegylated Liposomal Irinotecan Hydrochloride Trihydrate for Treating Pancreatic Cancer After Gemcitabine: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. 5-FU, AC, ICER, ITC, LV, NICE, QALY
21  2018 Pembrolizumab for Locally Advanced or Metastatic Urothelial Cancer Where Cisplatin is Unsuitable: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. CS, ICER, NICE, OS, PFS, QALY, STA
22  2018 Pirfenidone for Treating Idiopathic Pulmonary Fibrosis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. BSC, IPF, NICE, RCTs
23  2018 Pomalidomide with Dexamethasone for Treating Relapsed and Refractory Multiple Myeloma Previously Treated with Lenalidomide and Bortezomib: An Evidence Review Group Perspective of an NICE Single Technology Appraisal. Bor, BTD, CC, ICERs, KSR, LEN, NICE, PAS, POM, QALY, RCT, RRMM, STA
24  2018 Ponatinib for Treating Acute Lymphoblastic Leukaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. allo-SCT, BSC, ICERs, NICE, PAS, QALY, STA
25  2018 Ponatinib for Treating Chronic Myeloid Leukaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. allo-SCT, AP, BP, BSC, CML, CP, MAIC, NICE, QALY
26  2018 Reslizumab for Treating Asthma with Elevated Blood Eosinophils Inadequately Controlled by Inhaled Corticosteroids: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. AC, NICE, SHTAC, STA
27  2018 Sarilumab for Previously-Treated Moderate or Severe Rheumatoid Arthritis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. bDMARDs, cDMARDs, HAQ-DI, ICERs, MTX, NHS, NICE, NMAs, QALY, RA, RTX, SAR, STA, TNFis
28  2018 Strimvelis for Treating Severe Combined Immunodeficiency Caused by Adenosine Deaminase Deficiency: An Evidence Review Group Perspective of a NICE Highly Specialised Technology Evaluation. ADA-SCID, HSCT, HST, ICERs, MUD, NICE, QALY
29  2018 Ticagrelor for Secondary Prevention of Atherothrombotic Events After Myocardial Infarction: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. AC, ASA, CS, ICER, KSR, MI, NICE, PSA, QALY, RCT
30  2018 Tofacitinib for Treating Rheumatoid Arthritis After the Failure of Disease-Modifying Anti-rheumatic Drugs: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. bDMARDs, cDMARD-IR, cDMARDs, EULAR, MTX, NICE, NMA, PAS, QALY, RA, RCTs, RTX, TOF
31  2018 Trifluridine-Tipiracil for Previously Treated Metastatic Colorectal Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. AC, BSC, CS, HR, ICER, KSR, NICE, OS, PFS
32  2018 Ustekinumab for Treating Moderately to Severely Active Crohn's Disease after Prior Therapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. CD, CHE, CRD, NICE, NMA, STA
33  2018 Venetoclax for Treating Chronic Lymphocytic Leukaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. BCRi, BSC, CLL, HRs, ICERs, NHS, NICE, ORR, OS, PC, PFS, QALY, R/R, STA
34  2017 A Review of Ruxolitinib for the Treatment of Myelofibrosis: A Critique of the Evidence. BAT, CHE, CRD, ICER, IPSS, NHS, NICE, PAS, QALY, RCTs, STA
35  2017 Abiraterone Acetate for the Treatment of Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer: An Evidence Review Group Perspective of an NICE Single Technology Appraisal. AA, AAP, AC, BSC, CS, ICERs, ITT, KSR, mCRPC, NICE, PAS
36  2017 Adalimumab for Treating Moderate-to-Severe Hidradenitis Suppurativa: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. ACD, HS, ICER, NICE, PAS, PSS, QALY, STA
37  2017 Azacitidine for Treating Acute Myeloid Leukaemia with More Than 30% Bone Marrow Blasts: An Evidence Review Group Perspective of a National Institute for Health and Care Excellence Single Technology Appraisal. BSC, CCR, ICER, NICE, QALY
38  2017 Cabazitaxel for Hormone-Relapsed Metastatic Prostate Cancer Previously Treated With a Docetaxel-Containing Regimen: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. ICER, mHRPC, NHS, NICE, NMA, PASs, QALY, STA
39  2017 Certolizumab Pegol for Treating Rheumatoid Arthritis Following Inadequate Response to a TNF-alpha Inhibitor: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. AC, bDMARDs, CZP, MTX, NICE, NMA, QALYs, RA, RCTs, RTX, STA, TNFi
40  2017 Crizotinib for Untreated Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. ALK-positive, ICER, NICE, NSCLC, OS, PAS, PFS, QALY
41  2017 Degarelix for Treating Advanced Hormone-Dependent Prostate Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. ICER, LHRH, NICE, QALY, RCT, SCC
42  2017 Evolocumab for Treating Primary Hypercholesterolaemia and Mixed Dyslipidaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. CVD, HeFH, ICERs, LDL-C, NICE, PAS, QALY, STA
43  2017 Olaparib for Maintenance Treatment of BRCA 1 or 2 Mutated, Relapsed, Platinum-Sensitive Ovarian, Fallopian Tube and Peritoneal Cancer in People Whose Relapsed Disease has Responded to Platinum-Based Chemotherapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. CI, CS, HR, ICER, NHS, NICE, OC, OS, PFS, PSR, PSS, QALY
44  2017 Ramucirumab for Treating Advanced Gastric Cancer or Gastro-Oesophageal Junction Adenocarcinoma Previously Treated with Chemotherapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. AC, BSC, GC/GOJ, ICER, KSR, NICE, NMA, PAC, PAS, QALY, RAM, STA
45  2017 Talimogene Laherparepvec for Treating Metastatic Melanoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. AC, GM-CSF, ICERs, LRiG, NICE, PAS, QALY, T-VEC
46  2016 Apremilast for the Treatment of Moderate to Severe Plaque Psoriasis: A Critique of the Evidence. CHE, CRD, NICE, PASI, STA
47  2016 Daclatasvir for the Treatment of Chronic Hepatitis C: A Critique of the Clinical and Economic Evidence. ICER, NICE, SVR12
48  2016 Evolocumab for Treating Primary Hypercholesterolaemia and Mixed Dyslipidaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. ICERs, LDL-C, NICE, PAS, QALY, STA
49  2016 Ledipasvir-Sofosbuvir for Treating Chronic Hepatitis C: A NICE Single Technology Appraisal-An Evidence Review Group Perspective. AC, CS, GT1, ICERs, LDV/SOF, NICE, RBV, ScHARR, SVR12
50  2016 Lenalidomide for the Treatment of Low- or Intermediate-1-Risk Myelodysplastic Syndromes Associated with Deletion 5q Cytogenetic Abnormality: An Evidence Review of the NICE Submission from Celgene. AC, ICER, KSR, MDS, NICE, OS, PAS, RBC, STA
51  2016 Malaria Policy Advisory Committee to the WHO: conclusions and recommendations of eighth biannual meeting (September 2015). MPAC
52  2016 Rivaroxaban for Preventing Atherothrombotic Events in People with Acute Coronary Syndrome and Elevated Cardiac Biomarkers: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. ACS, ICER, NHS, NICE, NSTEMI, QALY, STEMI
53  2016 The Clinical and Cost Effectiveness of Apremilast for Treating Active Psoriatic Arthritis: A Critique of the Evidence. AC, DMARDs, HAQ, ICER, NICE, PsA, QALY, STA, TNF
54  2016 The Clinical and Cost Effectiveness of Ustekinumab for the Treatment of Psoriatic Arthritis: A Critique of the Evidence. ICER, NICE, PAS, PsA, STA, TNF-alpha
55  2016 The Clinical and Cost Effectiveness of Vortioxetine for the Treatment of a Major Depressive Episode in Patients With Failed Prior Antidepressant Therapy: A Critique of the Evidence. ICER, MADRS, MDEs, NICE, QALY, STA
56  2016 Trastuzumab Emtansine for Treating HER2-Positive, Unresectable, Locally Advanced or Metastatic Breast Cancer After Treatment with Trastuzumab and a Taxane: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. AE, HER2, ICER, NICE, PAS, PFS, ScHARR-TAG
57  2016 Vedolizumab for the Treatment of Adults with Moderate-to-Severe Active Ulcerative Colitis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. NICE, p value not reported, STA, TNF, UC
58  2016 Vedolizumab for Treating Moderately to Severely Active Crohn's Disease After Prior Therapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. ICER, NICE, QALY, ScHARR
59  2015 Alteplase for the treatment of acute ischaemic stroke: a NICE single technology appraisal; an evidence review group perspective. ICER, NICE
60  2015 Dabrafenib for Treating Unresectable, Advanced or Metastatic BRAF V600 Mutation-Positive Melanoma: An Evidence Review Group Perspective. AC, ICERs, ITC, LRiG, NHS, NICE, OS, PAS, PFS, QALY, STA
61  2015 Eribulin for the treatment of advanced or metastatic breast cancer: a NICE single technology appraisal. AC's, CI, HR, HRQoL, ICER, ITT, NICE, OS, PFS, TPC
62  2015 Evidence Review Group (ERG) Critique of Systematic Reviews (SR) Submitted to Nice as Part of Single Technology Appraisals (STA) or Multiple Technology Appraisals (MTA) in the Last Three Years. MTA, SR, STA
63  2015 Ipilimumab for Previously Untreated Unresectable Malignant Melanoma: A Critique of the Evidence. BSC, ICER, NICE, OS, QALY, RCT
64  2015 Nalmefene for Reducing Alcohol Consumption in People with Alcohol Dependence: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. NICE, NICE CG115, QALYs
65  2015 Pertuzumab in combination with trastuzumab and docetaxel for the treatment of HER2-positive metastatic or locally recurrent unresectable breast cancer. AC, CLEOPATRA, ICERs, LRiG, NICE, OS, pertuzumab arm, PFS, STA
66  2015 Sipuleucel-T for the Treatment of Metastatic Hormone-Relapsed Prostate Cancer: A NICE Single Technology Appraisal; An Evidence Review Group Perspective. AA, AC, APC, BSC, CI, CS, HR, ICER, NICE, PBO, QALY, RCTs
67  2015 The Clinical and Cost Effectiveness of Aflibercept in Combination with Irinotecan and Fluorouracil-Based Therapy (FOLFIRI) for the Treatment of Metastatic Colorectal Cancer Which has Progressed Following Prior Oxaliplatin-Based Chemotherapy: a Critique of the Evidence. ICER, NICE, OS, PFS, QALY, RCT
68  2014 Rituximab in combination with corticosteroids for the treatment of anti-neutrophil cytoplasmic antibody-associated vasculitis: a NICE single technology appraisal. AAV, ANCA, NICE, STA
69  2013 Aripiprazole for the treatment and prevention of acute manic and mixed episodes in bipolar I disorder in children and adolescents: a NICE single technology appraisal. NICE
70  2013 Bivalirudin for the treatment of ST-segment elevation myocardial infarction: a NICE single technology appraisal. AC, GPIs, HRQoL, ICER, MI, NICE, PPCI, RCT, ScHARR, STA, STEMI
71  2013 Cabazitaxel for the second-line treatment of metastatic hormone-refractory prostate cancer: a NICE single technology appraisal. mHRPC, NICE, ScHARR-TAG
72  2013 Dabigatran for the prevention of stroke and systemic embolism in atrial fibrillation: A NICE single technology appraisal. AF, DBG110, DBG150, ICER, NICE, QALY
73  2013 Golimumab for the treatment of ankylosing spondylitis: a NICE single technology appraisal. AEs, AS, BASDAI, CEA, CrIs, HRQoL, ICER, MS, MTC, NICE, RCTs, RR, STA, TA, TNF-alpha
74  2013 Golimumab for the treatment of rheumatoid arthritis after the failure of previous disease-modifying antirheumatic drugs: a NICE single technology appraisal. ACR70, DMARDs, HAQ, NICE, RA, ScHARR-TAG, STA, TNF
75  2013 Pazopanib for the first-line treatment of patients with advanced and/or metastatic renal cell carcinoma : a NICE single technology appraisal. ECOG, HR, IFN-alpha, NICE, PFS, STA
76  2013 Retigabine for the adjunctive treatment of adults with partial-onset seizures in epilepsy with and without secondary generalization : a NICE single technology appraisal. AEDs, NICE, OR, RCTs, STA
77  2013 Rituximab for the first-line maintenance treatment of follicular non-Hodgkin's lymphoma : a NICE single technology appraisal. AC, FNHL, HR, LRiG, MTE, NICE, PFS, R-CTX, RTX, STA
78  2013 Ruxolitinib for the treatment of myelofibrosis: a NICE single technology appraisal. BAT, COMFORT, NHS, NICE, RCTs
79  2013 Trabectedin for the treatment of advanced metastatic soft tissue sarcoma: a NICE single technology appraisal. AC, aMSTS, BSC, ICER, NICE, OS, PAS, PFS, RCT, ScHARR, STA
80  2013 Trastuzumab for the treatment of HER2-positive metastatic gastric cancer : a NICE single technology appraisal. AGC, CHE, CRD, HER2, NICE, STA
81  2013 Vemurafenib for the treatment of locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma: a NICE single technology appraisal. AC, BRIM 3, ICER, LRiG, NICE, RCT, STA
82  2012 Bevacizumab for metastatic colorectal cancer: a NICE single technology appraisal. ICERs, mCRC, NICE, PAS, ScHARR, STA
83  2012 Dabigatran etexilate for the prevention of venous thromboembolism in patients undergoing elective hip or knee surgery: a NICE single technology appraisal. AC, DBG, MTC, NICE, THR, TKR, VTE
84  2012 Dronedarone for the treatment of atrial fibrillation: a NICE single technology appraisal. AAD, AF, ICERs, NICE, STA
85  2012 Eltrombopag for the treatment of chronic immune or idiopathic thrombocytopenic purpura: a NICE single technology appraisal. ICER, ITP, NICE, OR, STA, TAR
86  2012 Golimumab for the treatment of psoriatic arthritis: a NICE single technology appraisal. ACR, DMARDs, ICERs, NICE, PASI, PsA, PsARC, RR
87  2012 Omalizumab for the treatment of severe persistent allergic asthma in children aged 6-11 years: a NICE single technology appraisal. CHE, CRD, CSS, NICE, RR
88  2011 Bevacizumab in combination with a taxane for the first-line treatment of HER2-negative metastatic breast cancer. AVADO, ICERs, MBC, PFS, RCT
89  2011 Denosumab for the prevention of osteoporotic fractures in post-menopausal women: a NICE single technology appraisal. NICE, RR, STA, WTP
90  2011 Denosumab for the prevention of osteoporotic fractures in postmenopausal women. RR
91  2011 Eltrombopag for the treatment of chronic idiopathic (immune) thrombocytopenic purpura (ITP). ICER, ITP, MS, NICE, QALY
92  2011 Erlotinib monotherapy for the maintenance treatment of non-small cell lung cancer after previous platinum-containing chemotherapy: a NICE single technology appraisal. ICERs, LRiG, NICE, NSCLC, OS, PFS
93  2011 Febuxostat for the management of hyperuricaemia in patients with gout: a NICE single technology appraisal. NICE, ScHARR-TAG, STA
94  2011 Golimumab for the treatment of psoriatic arthritis. ACR, CI, HAQ, ICERs, MTC, PASI, PsA, PsARC, QALYs, RCT, RR, TNF
95  2011 Liraglutide for the treatment of type 2 diabetes. BMI, LEAD-5, NICE, QALYs, SBP
96  2011 Ofatumumab for the treatment of chronic lymphocytic leukaemia in patients who are refractory to fludarabine and alemtuzumab: a critique of the submission from GSK. BSC, CLL, DR, MS, NICE, OS, PFS
97  2011 Prucalopride for the treatment of women with chronic constipation in whom standard laxative regimens have failed to provide adequate relief. MS, PAC-QOL, PAC-SYM
98  2011 Trabectedin for the treatment of relapsed ovarian cancer. MTC, NICE, PLDH, QALY, RCT
99  2011 Trastuzumab for the treatment of HER2-positive metastatic adenocarcinoma of the stomach or gastro-oesophageal junction. 5-FU, CF, ECF, EOX, FISH, HCF, HER2, ICER, IHC, QALYs, RCT
100  2010 Alitretinoin for severe chronic hand eczema: a NICE single technology appraisal. CHE, DLQI, HRQoL, ICERs, NICE, PUVA, RCT, STA